Cerebrolysin
Cerebrolysin is not a single peptide but a manufactured mixture of low-molecular-weight peptide fragments and free amino acids derived from enzymatically processed porcine brain tissue, used clinically in some countries (not including the US) for dementia and stroke recovery, with modest and debated efficacy in meta-analyses.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Cerebrolysin is produced by standardized enzymatic breakdown and purification of porcine brain protein, yielding a defined mixture (roughly a quarter of its content being peptides under about 10 kDa) intended to mimic the pleiotropic activity of endogenous neurotrophic factors rather than acting as a single-receptor ligand. Proposed mechanisms include neurotrophic-factor-like trophic support, anti-inflammatory and anti-apoptotic effects, and promotion of neurogenesis and synaptic plasticity, though because it is a complex mixture its effects cannot be attributed to one defined molecular target.
Typical results seen in research
A meta-analysis of randomized controlled trials found modest cognitive benefit in mild-to-moderate Alzheimer's disease compared with placebo, and separate trials have reported benefit in vascular dementia and post-stroke recovery outcomes; however, effect sizes are generally small, trial quality and blinding have been criticized, and results are heterogeneous across studies. Cerebrolysin should be described as having real but modest and debated clinical trial support, not as a well-established disease-modifying therapy.
How it’s commonly used
Cerebrolysin is administered by intravenous infusion or intramuscular injection in clinical settings, typically as a course of treatments rather than a single dose.
- Journal of Neural Transmission · 2007 Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease
- Journal of Neural Transmission · 2002 Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
- Neuroscience · 2025 The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.